The company intends to use the funds to advance its primary ciliary dyskinesia and cystic fibrosis clinical development programs and to expand its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) pipeline to include mRNA and gene correction therapeutics for central nervous system, lung, liver and musculoskeletal indications.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1455 Adams Dr.
Menlo Park, CA 94025
USA

Phone

469-306-1618

Website

www.recodetx.com

Email Address

[email protected]

Overview

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).

Profile

Social Media

ReCode Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Lockhart

Browse more venture capital transactions:

Prev: 9/19/2023: ARX venture capital transaction
Next: 9/19/2023: Hibob venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary